Comparative pharmacokinetics and pharmacodynamics of intravenous artelinate versus artesunate in uncomplicated Plasmodium coatneyi-infected rhesus monkey model

Paktiya Teja-Isavadharm1*, Duangsuda Siriyanonda1, Maneerat Rasameesoraj1, Amporn Limsalakpeth1, Nitima Chanarat1, Natthasorn Komcharoen2, Peter J. Weina3,4, David L. Saunders1,5, Montip Gettayacamin2,6 and R. Scott Miller1,7

Abstract

Background: The US Army designed artelinate/lysine salt (AL) to overcome the instability of sodium artesunate in aqueous solution (AS). To select the most efficacious artemisinin treatment, direct comparison was performed in an uncomplicated non-human primate malaria model.

Methods: Splenectomized rhesus monkeys were inoculated with Plasmodium coatneyi and on day six, single equimolar loading dose of IV AL (11.8 mg kg⁻¹) or IV AS (8 mg kg⁻¹) were administered followed by 1/2 the first dose once daily for 2 more days. Blood smear were performed twice daily and the number of parasites were counted microscopically. Blood samples were obtained after the first dose within 6 h for pharmacokinetic (PK) and ex vivo pharmacodynamic evaluation by simultaneously measuring plasma drug concentration and anti-malarial activity against Plasmodium falciparum in vitro.

Results: The anti-P. coatneyi in vivo activity of both compounds were comparable, but the ex vivo anti-P. falciparum potency of the IV AS regimen as administered was sevenfold higher than that of IV AL. Comparing in vivo pharmacodynamics of AL and AS, daily assessed parasite counts showed comparable 99% parasite clearance times (PC99: 2.03, 1.84 day), parasite clearance rates (5.34, 4.13 per min) and clearance half-life (PCt½: 7.79, 10.1 h). This study showed strong and significant inverse correlation between PCt½ and t½ of AS + DHA, and AUC0–∞ of DHA, and correlated with V/z of AS (r² > 0.7, p ≤ 0.002). Lastly, following IV AL, there was a modest inverse correlation between PCt½ and Cmax (r² 0.6, p ≤ 0.04). Although all tested monkeys recrudesced subsequently, two died following AL regimen before parasite clearance. While the aetiology of those deaths could not be definitively determined, pathologic evidence favoured a sepsis-like syndrome and suggested that severe malaria was more likely than drug toxicity.

Conclusion: The model demonstrated that both AS and DHA contributed to the anti-malarial activity of IV AS, while IV AL activity was largely restricted to the parent drug. Parasite clearance was strongly and linearly dependent on drug exposure for both artemisinin regimens. However, IV AS had higher ex vivo potency against P. falciparum, leading to an IND filing for GMP manufactured AS in the United States.

*Correspondence: paktiyat@gmail.com
1 Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, 315/6 Rajvithi Road, Bangkok 10400, Thailand
Full list of author information is available at the end of the article

© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite reductions in morbidity and mortality, severe malaria still kills a half a million persons worldwide each year, including travelers [1]. Severe malaria occurs when *Plasmodium* infection is complicated by serious organ failure or metabolic abnormalities which develop rapidly and can progress to death within 24–48 h, and requires parenteral therapy. Since 1991, quinidine gluconate remains the only FDA-approved drug available for severe malaria infection in the US. It is available in limited supply, requires continuous infusion with a loading dose in an intensive care unit for cardiac and glycaemic monitoring, and resistance has been documented [2, 3]. Artesunate (AS) was developed and tested as a replacement for quinine. AS has now been receiving WHO-prequalification status since 2010 and adopted as the recommended treatment; but a Good Manufacture Practice (GMP) product remains inaccessible in many countries [4]. Intravenous AS was associated with a lower risk of hypoglycaemia and has been shown to significantly reduce the risk of death from severe malaria compared to IV quinine [5, 6]. Artesunate is also a more practical option in resource-poor settings since administration is simpler (by bolus injection) and does not require slow rate-controlled infusion as well as cardiac monitoring [5, 7].

During the testing of parenteral artesunate, the US Army, through the Walter Reed Army Institute of Research, had considered developing another artemisinin derivative, artelanic acid-L-lysine salts (AL) and was patented in 1988 [8] as anti-malarial agents for clinical treatment of severe malaria. Artelinate, a semi-synthetic derivative of artemisinin, does not convert readily to dihydroartemisinin (DHA) was designed to overcome the instability of sodium artesunate in aqueous solution, which must be prepared at the bed side before injection. Pre-clinical efficacy and toxicity studies were used to select one of these artemisinins candidates as potential treatments for severe malaria and eventual FDA registration. Comparative anti-malarial efficacy of IV AL and AS in rat malaria model showed that AL had a superior anti-malarial potency than AS in terms of parasitaemia clearance [9]. However, this evidence also showed that AL was more toxic than AS in rats [10, 11].

Several non-human primate malaria models serve as useful surrogates to evaluate new drugs prior to testing in humans. *Plasmodium coatneyi* is primate malaria that causes tertian malaria in splenectomized Asian macaques, complicated by sequestration of the infected erythrocytes and a high mortality rate in untreated animals [12]. This model most closely mimics severe and complicated malaria caused by *Plasmodium falciparum* [13, 14]. Limited efforts have used this model to study toxicity of drug due to brain-damage induced by lipid-soluble depot artemisinins [13, 15]. The present study compared the pharmacokinetics and pharmacodynamics of AL and AS in the uncomplicated *P. coatneyi* infected rhesus monkey model to test the new candidate drugs for severe malaria treatment.

Methods
The United States Army Medical Component, Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS) Institutional Animal care and Use Committee and the Animal Use Review Division, US Army Medical Research and Materiel Command reviewed and approved the protocol. Research was conducted in 2002 in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, NRC Publication, 1996 edition. The USAMC-AFRIMS animal care and use programme has been accredited by Association for Assessment and Accreditation for Laboratory Animal Care International since 1999.

*Plasmodium coatneyi*-Rhesus monkey model
*Plasmodium coatneyi*-infected RBCs (wild-type strain originally donated by W.E. Collins, CDC, Atlanta, GA) were maintained as cryopreserved stablates at AFRIMS, Bangkok, Thailand. The stablate stock was tested and confirmed negative for B-virus, SRV, SIV and STV-1 to ensure no adventitious viruses transmission were introduced to the monkey colony. Twenty-two adult colony-born, Indian-origin rhesus macaques (*Macaca mulatta*) naïve monkeys were splenectomized and recovered well more than 1 month prior to entering the study. All monkeys were free from B-virus, SIV, SRV and STLV antibodies. Animal health screening included complete physical examination, CBC, ALT and creatinine. Twenty-two animals were randomized to two experiments of 11 monkeys. Each experiment included ten experimental monkeys (IV AL and AS) and one control animal. The control monkeys received intramuscular quinine treatment and the experimental animals received intravenous artemisinin candidates.
Infected donor monkey

For each experiment, after thawing a stabilate of *P. coatneyi*-infected erythrocytes, 1 ml aliquot was inoculated intravenously to the test monkey. The monkey was sedated with ketamine HCl (5–15 mg kg⁻¹, IM) for this procedure. Parasitaemia levels were monitored daily. After the parasite density reached ≥50,000 parasites µL⁻¹, 5–20 ml of blood was drawn from a femoral vein into a heparinized tube. Blood was divided into 1 ml aliquots (about 5 × 10⁶ RBC with a 1 % parasitaemia) for inoculation of the study animals. Then, the donor animal was treated with chloroquine hydrochloride 10 mg kg⁻¹ day⁻¹ IM for 5–7 days. This was the standard treatment regimen for *P. coatneyi*-infected control animals at AFRIMS based on local protocols. The injectable chloroquine hydrochloride (Aralen™ 40 mg base/ml) was given by intramuscular route. The injection has been practical since it can be given with minimal animal handling using the “squeeze cage” mechanism. Animals were monitored daily and the treatment range of 5–7 days was used as the benchmark for when blood smear evaluation became negative.

Parasitaemia and clinical monitoring

Animals were observed at least twice daily to assess clinical signs and correlates of severe malaria. Based on our previous model validation, blood smears were performed to detect malaria parasites starting prior to inoculation on day 0 and continued daily (0700–0800 h). The monkeys were physically restrained in the squeeze cage restraint apparatus and approximately 0.1–0.2 ml whole blood was collected from each monkey by lancet puncture of the lateral auricular vein. Thick and thin smears were made on the same microscope glass slide and subsequently fixed in methanol and stained with Giemsa. When the smears were positive, white blood cell count (WBC) and/or red blood cell count (RBC) were also performed using automated haematology analyzer Sysmex K800 to calculate parasite density. Haematocrits were checked as needed. At study days 6–12, additional blood samples were obtained from all animals in the afternoon (1500–1600 h) to monitor parasitaemia levels. Daily blood smears were continued until two consecutive days with negative smears. Then the smear monitoring schedule was reduced to two times weekly for 2 weeks and then weekly for 6 weeks after completion of the last treatment. Treatment failures and/or recrudescence were treated with IM quinine dihydrochloride 60 mg kg⁻¹ loading dose, followed by 30 mg kg⁻¹, every 8 h for 3 days.

Treatment was initiated at parasitaemias ≥3 % or >200,000 parasites µL⁻¹ (on study day 6 morning) due to rapid increasing in parasitaemia levels observed in previous model development and dose-ranging studies (unpublished data). Blood smear staining and parasitaemia determination took about 2 h. The first dose of treatment was decided after the results were confirmed. The eleven monkeys were treated as one cohort when the majority met the treatment criteria and allowed for practical blood drawing and processing for PK sampling. The control monkey received quinine treatment and the ten experimental animals received intravenous artemisinin derivative candidate. Animals were pole-and-collar trained and sat in restraining chairs to receive the IV injection and phlebotomy without the use of chemical restraint to avoid potential confounding and depression by concomitant anesthetic administration.

Chemicals

Artelinic acid (WR255663), 4-(10’ dihydro-artemisinin-oxyymethyl) benzoic acid hemihydrate, was prepared as an l-lysine salt (MW 573.719) powder at Walter Reed Army Institute of Research (WRAIR; Silver Springs, MD) and shipped to AFRIMS through WRAIR Chemical Information. Artesunic acid (MW 384.425) and 5 % sodium bicarbonate solution was obtained from Guilin Pharmaceutical, Guangxi, China and imported by Atlantic Pharmaceutical Co., Ltd., Bangkok, Thailand. Artelinate/lysine salt (AL) powder prepared with 1 g of the acid content was equivalent to 1.35 g of the salt weight. Intravenous AL was prepared from a stock solution containing 40 mg L⁻¹ of AL by dissolving the calculated amount of the AL salt in a solution of 0.45 % NaCl/0.1 % l-lysine (w/v), sterilized and filtered through 0.2 µm cellulose acetate. Additional IV solutions with the required concentrations of AL was made by appropriate dilution of the 40 mg L⁻¹ solution with normal (0.9 %) saline containing 0.1 % l-lysine, followed by filtration through a syringe filter prior to use. Intravenous artesunate/sodium salt (AS) was prepared by dissolving the acid in 5 % sodium bicarbonate just prior to injection per manufacturer instructions.

Dosing regimen

Single, equimolar doses 20 µmol of IV AL (11.8 mg kg⁻¹) and IV AS (8 mg kg⁻¹) were administered as a rapid bolus injection over a 1-min period. These doses were chosen as the minimal effective doses (from previous model development and validation studies, unpublished data) and blood was collected for pharmacokinetic analysis. After a week wash-out and recovery period, *P. coatneyi* (1 mL of >50,000 parasitized RBCs per microlitre or 5 × 10⁶ RBC with a 1 % parasitaemia) were inoculated from a donor monkey into all the monkeys. The treatment was initiated at day 6 after inoculation at a parasitaemia ≥3 % or >200,000 parasites µL⁻¹ when the cohort of animals was minimally symptomatic. Drugs were given
for 3 days with a loading dose initially followed by ½ of the first dose on the 2nd and 3rd days. Consequently, each monkey served as its own control for intra-subject variation, and differences are likely due to the disease effects from malaria infection.

**Blood collection and sample preparation**

Blood was collected for pharmacokinetic/pharmacodynamics (PK/PD) analysis after the first dose only due to rapid clearance of artemisinin derivatives. Heparinized blood was collected at 0, 5, 20, 40 min, 1, 3, and 6 h post-dose and plasma samples were separated within 2 h by centrifugation (1500g, 10 min). Aliquots of samples were made for simultaneous measurement by HPLC [16] and bioassay [14], and stored at −80 °C until analysis. All glassware was silanized before use with a 0.5 % aqueous solution (v/v) of Pierce Aquasil (Rockford, IL, USA) according to the manufacturer’s recommended procedure. Solid-phase extraction was performed on C-18 elution cartridge (3.0 ml, J.T. Baker Co.) using a VAC ELUTE SPS24 sample processing station (Analyticchem International, Harbour City, CA, USA). The cartridge was preconditioned by sequential washing with 2.5 ml acetonitrile, 2.5 ml methanol and 2.5 ml water. One ml of distilled water was added to the cartridge before adding plasma sample (0.5 ml). Then, the cartridge was washed with 2.5 ml distilled water, 2.5 ml of 0.05 % H3PO4 (pH 4.5) and 2.5 ml of 20 % acetonitrile and completely dried by closing the vacuum for 15 min. The analytes were collected by eluting with 0.5 ml methanol three times and then with 0.5 ml 90:10 n-butyl chloride: ethyl acetate twice. The organic phases were pooled. The combined organic phases were then evaporated to dryness under a stream of nitrogen at room temperature. Extraction residues were reconstituted with 50:50 ethanol: water (0.3 ml), at least 16 h before injection. The injection volume was 100 µl for all samples.

The plasma concentration of parent drugs, AL and AS, and their primary metabolites, DHA and 2-hydroxyartelinate (OHAL) respectively, were measured by HPLC with electrochemical detection in reductive mode (HPLC-ECD) [16], which was the only method for artemisinin compounds then (Additional files 1 and 2). The total anti-malarial activity of the drug and all active metabolite(s) in plasma were measured using a previously published method [14]. In brief, plasma was incubated with protein A to remove the majority of immunoglobulin (IgG) that results in the lysis of the parasites in the erythrocytes (heat treatment was not used due to the effect on the stability of artemisinin derivatives in plasma). After centrifugation, the supernatant (100 µL) was transferred to a 96-well flat bottom plate. Twofold serial dilutions were then made using heat inactivated pooled control serum (human: rhesus = 1:1). A suspension of malaria (W2 clone) infected erythrocytes was added to each well. The microtitre plate was placed into a gas-tight plexiglass chamber, flushed with a gas mixture of 90 % CO2, 5 % O2, and 5 % N2, and placed into an incubator (37 °C). Following 24 h incubation, the plate was removed from the chamber and pulsed with [3H]-hypoxanthine solution to each well and incubated for another 18–20 h before harvesting. The incorporation of [3H]-hypoxanthine by the parasites in each well was determined by counting in a scintillation counter.

A dose–response curve for each plasma sample was constructed by plotting [3H]-hypoxanthine uptake on the Y-axis against the corresponding dilution factor on the X-axis after logarithmic transformation. The dilution factor value that inhibits parasite growth by 50 % (DF50)
of each plasma sample was determined. Using the DF_{50} value, the anti-malarial activity of the plasma sample was extrapolated from a linear standard curve using DHA, the most potent artemisinin derivative, and expressed as DHA equivalents.

**Assessment of parasite counts**

Blood smear were collected once daily in the morning. Once positive parasitaemia was observed and reached 2000 parasites µL\(^{-1}\), blood smears were collected twice, in the morning and afternoon. Blood for slides preparation were collected from ear for thick and thin smear preparation. Blood films on glass slides were air dried, fixed with 100 % methanol, stained with Giemsa, and read under \(\times 100\) magnification oil emersion for parasite determination.

First, a thick smear was performed for parasite detection by reading the slides at least 50 fields under \(\times 100\) magnification oil emersion. If no parasite was detected in all 50 fields, “negative” parasitaemia was reported. If on average five parasites were detected/field under \(\times 100\) magnification oil emersion, the number of parasitized RBCs was counted per 100 WBC. This number was used for the number of parasites µL\(^{-1}\) of blood using the formula:

\[
\text{Parasites µL}^{-1} \text{ blood} = \left[ \frac{\text{number of counted parasites}}{100 \times \text{(WBCs)}} \right] \times \text{WBC count µL}^{-1} \text{ blood}
\]

Blood CBC was determined by automated haematology analyzer Sysmex K800 every other day. When parasite density was greater than ten parasites/field, parasites were counted per 1000 RBC. Thin smear was used when number of parasite was greater than five parasites per field in thick film. For counting parasite density/RBC, a grid micrometre was used and the number of parasitized RBCs was used for calculation. If the parasite density was less than ten parasites µL\(^{-1}\) the determination of parasitaemia was counted per 100 WBC (calculation method of parasite number was the same as thick smear).

The percentage of infected RBC was determined by enumerating the number of infected RBCs in relation to the number of uninfected RBCs. One thousand RBCs were counted and calculated as follows:

\[
\% \text{ infected RBCs} = \left( \frac{\text{No. infected RBCs}}{\text{Total No. RBCs counted}} \right) \times 100
\]

The number of asexual parasites µL\(^{-1}\) of whole blood was determined by counting white blood cells (WBC) in high-power fields containing a total of 500 parasites if the ratio of parasites/WBC was more than one, or the number of parasites per 1000 WBCs was counted if the ratio of parasites/WBC was less than one. The parasitaemia level was calculated as the product of the parasite/WBC ratio and the WBC count (microscope field that is well-populated with WBCs (20 WBCs/field) and five views were used for parasitaemia count).

**In vivo pharmacodynamic (iPD) analysis**

The parasite density-time curve was constructed and the parasite clearance parameters were estimated using Parasite Clearance Estimator [17]. The parameters were parasite clearance rate (PCR), clearance half-life (PCR\(_{t_{50}}\)), PC50, PC95, PC99 (PC\(_n\)—defined as the time from initiation of treatment to the time parasites were cleared by \(n\) %). In addition, the parasite clearance time (PCT) by conventional method (defined as the time from initiation of treatment to the time the first two consecutive negative blood smears) was assessed by microscopy.

**Pharmacokinetic analysis**

Non-compartmental analysis was used to derive pharmacokinetic parameters of AS and its metabolite DHA, AL and its metabolite OHAL, using WinNonlin™ Standard Edition, v 2.1 (Pharsight Corporation, Cary, NC, USA). The PK parameters determined were the elimination rate constant (\(\lambda_z\)) was calculated by least-squares regression analysis of the ln-linear portion of the plasma concentration–time curve (the number of time points >3). The elimination half-life (\(t_{1/2}\)) was calculated from the ratio of 0.693/\(\lambda_z\), the maximum concentration (C\(_\text{max}\)) in plasma and the time to reach C\(_\text{max}\) after dosing (T\(_\text{max}\)) were obtained by inspection, the area under the concentration–time curve (from time zero to 20 min, AUC\(_0\text{–}20\)\(\text{min}\)) and zero to infinity, AUC\(_\text{0–}\infty\) was estimated by the linear trapezoidal rule. The apparent total body clearance (Cl) and volume of distribution (V\(_z\)) associated with the terminal phase were calculated as dose/AUC, and Cl/\(\lambda_z\), respectively.

**Statistical analysis**

Statistical comparison between dosage regimens was performed using the Mann–Whitney U test and all the values reported were in median with 25th and 75th interquartile. The correlation between two variables was performed using simple linear regression model with least square method. Results were considered statistically significant when the p value was <0.05. (Prism 6 for Windows v. 6.01)

**Results**

**Clinical results and in vivo pharmacodynamics (iPD)**

Monkeys in the two treatment groups had comparable age and weight (Table 1). The parasite density of each control
monkey receiving quinine were 773,550 and 510,260 parasites μL⁻¹ for AL and AS group, respectively, which were within the range of the corresponding experimental monkeys. Parasite clearance-time profiles were shown in Fig. 1a–c (Additional file 4). Although animals treated with IV AL had statistically significant higher starting parasite density (727,850 vs 261,452; p 0.0005) and longer PC95 (1.22 vs 0.85 days, p 0.01), there were not significantly different in the PC99 (2.03 vs 1.84 day, p 0.3), PCR (5.34 vs 4.13 count.min⁻¹, p 0.1), and PCt1/2 (7.79 vs 10.1 h, p 0.1). Both formulations cleared the parasites so rapidly (Fig. 1d) that there were not sufficient data points to determine PC50 for all animals, only 4 of 8 for IV AL and 3 of 10 for IV AS with their corresponding PC50 values varying from 2.72–10.9 h and 0.32–5.88 h respectively. Unexpectedly after IV AL injection, there were two deaths in the infected animals within 2.5 h. The blood smear from both monkeys taken at time of death had comparable parasite densities of 1.2 × 10⁶ parasites μL⁻¹ with a percentage of parasitized red blood cells at 15 and 20 %. There was evidence of malaria and hepatic centrilobular degeneration consistent with shock. Though no clear etiology of death was determined, the findings favoured a diagnosis of severe malaria over drug toxicity, particularly since these doses were well tolerated by the other animals in the experiment. Six animals failed treatment because parasite counts never reached zero and PCT could be determined in only two animals at 4.0 and 5.3 days. In contrast, PCT could be determined in all monkeys in the IV AS group with a median of 7.0 days and IQR between 5.1 and 8.0 days. However, the two monkeys with the most rapid PCT occurred at 4.0 and 5.0 days. Median PCT of the remaining eight monkeys was 8.0 days with an IQR between 5.8 and 8.3 days. There was no relationship between PCT and initial parasite density. Furthermore, the parasites in the monkeys treated with IV AL, on average, kept increasing on day 4 after dosing while those treated with IV AS continued to decrease and cleared by 1 week post-treatment (Fig. 1c). However, parasites recrudesced in all monkeys at a median (range, n) of 13 (9–19, 10) days in the IV AS group and 6.5 (6–7, 2) days in the IV AL group.

Pharmacokinetics (PK)
The concentration–time profiles for each drug, its metabolite and anti-malarial activities for each animal are shown in Fig. 2 with mean values and 95 % CI shown in Fig. 3. Comparison of PK profiles for IV AL and IV AS showed no major differences between pre-infection and malaria infected states (Additional files 5, 6, 7, and 8). As a result, the PK and effect kinetics of ex vivo anti-malarial activity profiles or ex vivo pharmacodynamics (ePD) of the two IV candidates in infected monkeys were directly compared. All PK and ePD parameter estimates were derived from Fig. 2.

Table 1 The initial status of the monkeys and in vivo pharmacodynamics, parasites clearance values

| Parameters                  | Unit     | Rx     | Median | 25th IQT | 75th IQT | pᵃ       |
|-----------------------------|----------|--------|--------|----------|----------|----------|
| Monkey age                  | Year     | IV AL  | 8      | 8        | 10       | 1.0      |
| Monkey weight               | kg       | IV AL  | 8.4    | 6.7      | 9.0      | 0.8      |
| Parasite densityᵇ           | Count mL⁻¹| IV AL  | 727,850| 639,946  | 848,916  | <0.001   |
| Parasites/erythrocyte (PE)  | %        | IV AL  | 12.0   | 11.3     | 12.7     | <0.001   |
| Parasites clearance rate (PCR)| Count min⁻¹| IV AL  | 5.34   | 4.32     | 6.54     | 0.1      |
| Parasites clearance half-life (PCt₁/₂) | Hr     | IV AL  | 7.79   | 6.36     | 9.63     | 0.1      |
| 95 % Parasites clearance (PC95)| Day    | IV AL  | 1.22   | 1.13     | 1.27     | 0.01     |
| 99 % Parasites clearance (PC99)| Day    | IV AL  | 2.03   | 1.89     | 2.08     | 0.3      |
| Parasites clearance (PCT)c  | Day      | IV AL  | None   | None     | None     | NA       |

ᵃ Mann Whitney test
ᵇ Geometric mean and 95 % confidence interval
ᶜ Conventional method
Table 2 shows PK parameter estimates of IV AL compared to IV AS. Almost all PK variables for IV AL were significantly greater than that of IV AS (p < 0.0001). For parent drug AL, $C_{\text{max}}$ was twofold (60.2 vs 28.2 μM), $t_{1/2}$ was eightfold (28.2 vs 3.47 min), $AUC_{0-\infty}$ was 13-fold (3706 vs 288 μM.min), and $AUC_{0-20}$ was 3-fold (925 vs 288 μM.min) greater than that of AS. With the exception of the percentage of $AUC_{0-20}$ compared to total $AUC$ (%AUC$_{0-20}$), AL was 1/4 that of AS (24.6 vs 97.0 %). Moreover, the clearance (Cl) and the volume of distribution ($V_z$) of AS was 13-fold (72.3 vs 5.60 L kg$^{-1}$ min$^{-1}$) and 1.5-fold (0.397 vs 0.259 L kg$^{-1}$) greater than that of AL. The primary metabolites of AL and AS detected were OHAL and DHA respectively. The half-life values of OHAL (42.2 min) and DHA (31.1 min) were 1.5 and 9.0 fold longer than their parent drugs. In addition, the $AUC_{0-\infty}$ of OHAL was only 0.33 of its parent AL while that of DHA was 1.58 fold greater than its parent AS.

**Ex vivo pharmacodynamic (ePD)**

The effect kinetic parameters of ex vivo anti-malarial activity (measured by BA expressed as DHA equivalents), or ePD parameters of IV AL compared to IV AS were shown in Table 3. The anti-malarial activity $t_{1/2}$ values were essentially the same at 30 min. The $AUC_{0-\infty}$ was not significantly different between groups (426 μM.min for IV AL and 485 μM.min for IV AS). However, there were significant differences in both groups among the ePD parameters $C_{\text{max}}$ and $AUC_{0-20}$ where $C_{\text{max}}$ of IV AS (20.7 μM) was 2.7 times greater than that of IV AL (7.76 μM) and $AUC_{0-20}$ of IV AS (242 μM.min) was two-fold greater than IV AL (115 μM.min).

Figure 3 indicated that the anti-malarial activity of IV AS was contributed by both the parent drug AS and its active metabolite DHA until 20 min post-dose when the major compound in plasma transitioned to DHA. Parent drug AS was below the detection limit beyond 1 h post-dose and DHA was detected at its highest level as early as...
Fig. 2 Spaghetti plots of drug concentration–time profiles. Spaghetti plots of IV AL 11.8 mg kg\(^{-1}\) (a–d) and IV AS 8.0 mg kg\(^{-1}\) (e–h) in plasma of \(P.\) coatneyi infected rhesus monkeys showing drug concentration–time profiles of parent drugs (AL, AS), their metabolites (OHAL, DHA), combined parent + metabolite (AL + OHAL, AS + DHA), and their corresponding anti-malarial activities-time profiles against \(P.\) falciparum W2 clone.

Fig. 3 Mean drug concentration and anti—\(P.\) falciparum activity-time profiles. Drug concentration–time profiles (PK) measured by HPLC-ECD and anti-malarial activities-time profiles (ePD) simultaneously measured by ex vivo bioassay against \(P.\) falciparum W2 clone following equimolar 20 \(\mu\)mol kg\(^{-1}\) dose of a IV AL 11.8 mg kg\(^{-1}\), \(n = 8\) and b IV AS 8.0 mg kg\(^{-1}\), \(n = 10\) [reproduced from Fig. 5c (14)] in plasma of \(P.\) coatneyi infected rhesus monkeys. Top panel showed the parent drugs, their metabolites, combined parent and its metabolite, and anti-malarial activities of each parenteral regimen. Bottom panel showed direct comparison of c parents drugs (AL vs AS), d their metabolites (OHAL vs DHA), e combined parent + metabolite (AL + OHAL vs AS + DHA), and f their anti-malarial activities (IV AL vs IV AS). Values are mean ± 95 % CI.
5 min post-dose. As a result, AUC_{0-20} was 97% of AUC_{0-\infty} for AS and 53% for combined AS + DHA (Tables 2, 3). On the other hand, although OHAL metabolite was detected by HPLC-ECD, only AL was responsible for plasma anti-malarial activity (Fig. 3) and the AUC_{0-20} compared to the corresponding AUC_{0-\infty} for AL and AL + OHAL which were comparable at 24.6 and 21.4% respectively (Tables 2, 3). Furthermore, no DHA was found in plasma from either healthy or infected monkeys treated with IV AL.

Based on testing against the W2 clone, the in vitro potency of AS was comparable to DHA and was 4–5 times greater than that of AL. Since AS and its metabolite DHA contributed to the plasma anti-malarial activity, ex vivo potency was then determined from the AUC_{0-\infty} ratio between ePD and PK of the combined parent and its metabolite (Table 3). Thus, the ex vivo potency of IV AS (0.643) was sevenfold greater than IV AL (0.088).

### Pharmacokinetic/pharmacodynamic correlation analysis (least square regression)

#### PK/ePD

Of all the parameters estimated, there were very strong correlations between PK and ePD for both formulations (Table 4). Only the parent drug AL had a linear relationship between the ePD parameters and t_{1/2} and AUC_{0-\infty} (r^2 > 0.95, p < 0.0001). In contrast, t_{1/2} of DHA and AUC_{0-\infty} of AS + DHA for IV AS correlated linearly with ePD and to a smaller degree (r^2 > 0.74, p < 0.001 and r^2 > 0.85, p < 0.0002, respectively). As expected, the AUC_{0-20} values of the parent components of both IV preparations correlated well with ePD parameters (AL: r^2 0.75, p 0.005 and AS: r^2 0.80, p 0.0004). Only the C_{max} of AS, but not AL, strongly correlated with ePD parameters (r^2 0.81, p 0.0004).

#### PK or ePD/iPD

The concentration–time profiles (PK) of parent + metabolite and the parasite density-time profile (iPD) for both parenteral regimens were shown in Fig. 4. The PK and ePD parameters for IV AS significantly correlated with those of iPD; while only the ePD of IV AL showed significant correlation with iPD (Table 5). For IV AS, all PK parameters estimated, C_{max}, V_{z}, and Cl were significantly correlated well with the estimated parasite clearance parameters—PC_{t_{1/2}}, PCR, and PCT. The PK of parent AS showed its V_{z}, C_{max}, and Cl correlated well with PC_{t_{1/2}}, PCR, and PCT. The PK of DHA showed that AUC_{0-\infty} inversely and strongly correlated with PC_{t_{1/2}} (r^2 0.71, p 0.002) and PCT (r^2 0.53, p 0.02), respectively. The PK of DHA showed that AUC_{0-\infty} inversely and strongly correlated with PC_{t_{1/2}} (r^2 0.71, p 0.002) and PCT (r^2 0.53, p 0.02), respectively. The PK of combined AS + DHA showed its t_{1/2} inversely and strongly correlated with PC_{t_{1/2}} (r^2 0.77, p < 0.001), C_{max} correlated with PCR (r^2 0.62, p 0.007), and AUC_{0-\infty} inversely correlated with PCT (r^2 0.60, p 0.009).
the effect kinetic (ePD) of IV AS revealed that CI and $AUC_{0-\infty}$ correlated with PCT$_{1/2}$ ($r^2 = 0.57$, $p = 0.01$) and PCR ($r^2 = 0.52$, $p = 0.02$), respectively. On the other hand for IV AL, only $C_{\text{max}}$ correlated with PCT$_{1/2}$ and PCR ($r^2 = 0.61$, $p = 0.04$). Correlation analysis for PCT was not possible due to limited data points ($n = 2$). Figure 5 show the best PK-iPD with strong correlation ($r^2 > 0.7$) for IV AS and ePD-iPD for both regimens.

**Discussion**

While direct comparison of safety and efficacy were complicated by experimental factors, IV AS proved to have superior potency and more rapid parasite clearance compared to IV AL. Similar to prior studies in humans [15, 18, 19], PK/PD relationships for AS in monkeys revealed that the parent drug AS was rapidly converted to DHA and undetectable as early as 1 h post-dose. Activity and metabolic conversion were rapid. While AS was at fourfold higher concentration at 5 min post dose, only DHA was responsible for the observed anti-malarial activity roughly 20 min post-dose when plasma concentrations of DHA far exceeded AS. The $t_{1/2}$ of DHA was at least ninefold longer than AS. This is consistent with prior observations in healthy human studies attributing the effectiveness of AS in part to its rapid and extensive hydrolysis to DHA, achieving high initial drug levels [18]. Challenges inherent to the model limit experimental interpretation to some degree. The two experimental groups were inoculated and dosed separately rather than concurrently to allow sufficient time to adequately perform all procedures. Based on previous model development, the number of *P. coatneyi* parasites was expected to increase rapidly on study day 6. Therefore, blood parasitaemia was not measured prior to treatment in order to limit overall blood draws. Animals in the IV AS group were dosed first and morning parasitaemia levels varied

**Table 3** Pharmacokinetic parameters based on combined parent drug and metabolite levels and ex vivo pharmacodynamics (ePD)

| Pharmacokinetics Parameter | Rx | Ex vivo pharmacodynamic $^a$ | Combined P + M | Ex vivo potency $^b$ |
|---------------------------|----|-------------------------------|----------------|---------------------|
|                            | Unit | Median 25th IQT 75th IQT | Median 25th IQT 75th IQT | ePD/PK AS/AL | % $AUC_{0-20}$ |
| $C_{\text{max}}$          | mM   | IV AL 7.76 7.09 8.13 | IV AS 20.7 15.3 30.5 | 64.6 62.7 68.5 | 0.120 |
|                           |      | IV AL 35.2 31.3 44.4 | IV AS 36.3 30.6 44.8 | 0.587 4.89 |
| $t_{1/2}$                  | min  | IV AL 29.6 26.3 38.0 | IV AS 29.9 23.4 33.2 | 36.3 30.6 44.8 | 0.02 0.815 |
|                           |      | IV AL 29.1 23.7 31.4 | IV AS 29.1 23.7 31.4 | 1.028 1.26 |
| $AUC_{0-\infty}$          | mM min | IV AL 426 365 521 | IV AS 485 297 586 | 4911 3997 5827 | 0.088 |
|                           |      | IV AL 764 698 926 | IV AS 643 7.31 | 0.643 7.31 |
| $AUC_{0-20}$              | mM min | IV AL 115 109 121 | IV AS 242 172 348 | 1051 1007 1107 | 0.110 21.4 |
|                           |      | IV AL 404 373 502 | IV AS 598 544 529 | 5.44 52.9 |
| $C_{\text{max}}$          | L kg$^{-1}$ min$^{-1}$ | IV AL 48.5 39.5 57.0 | IV AS 43.0 35.7 70.6 | 0.83 0.83 |
| $V_z$                     | L kg$^{-1}$ | IV AL 2.14 1.91 2.32 | IV AS 1.84 1.41 2.87 | 0.57 0.57 |

$a$ Concentration reported as DHA equivalents

$b$ Mann Whitney Test

c $C_{\text{max}}$ maximum concentration of drug reached in plasma

d $t_{1/2}$ elimination half-life

$AUC_{0-\infty}$ area under the concentration–time curve from zero to infinity

$AUC_{0-20}$ area under the concentration–time curve from zero to 20 min

c CI apparent total body clearance

$V_z$ volume of distribution
between 0.5 and 10.1%, while parasitaemia in IV AL animals was between 7.1 and 20.2%, with roughly twofold higher median parasitaemia in the IV AL group (12%) compared to IV AS (6.6%) at initial dose. To some extent, this makes a meaningful in vivo PK/PD comparison difficult. Moreover, there were two deaths in the IV AL group limiting available data from those animals. Baseline parasitaemias in these animals (13.2 and 13.0%) were comparable to those of other animals. Both monkeys died when their parasite density reached $1.2 \times 10^6$ parasites $\mu$L$^{-1}$.

Parasitaemias were 15 and 20% respectively at 1 h apart suggesting that malaria was at the very least a major contributor to their demise. Although the aetiology of death could not be determined definitively, pathologic examination favored a systemic inflammatory syndrome consistent with severe malaria over drug toxicity.

The P. coatneyi model requires splenectomy in order to ensure adequate parasite infection and determine efficacy, and the results should be interpreted in light of this consideration. Normally, the spleen removes abnormal erythrocytes and intra-erythrocytic inclusions, including dead parasites which are removed from erythrocytes without erythrocyte destruction [20]. Infected RBCs may persist longer and likely delayed parasite clearance compared to what would have been

### Table 4 Correlation between PK and ePD

| Parameter       | Analyte       | IV AL          |        | IV AS          |        |
|-----------------|---------------|----------------|--------|----------------|--------|
|                 |               | a   | b   | $r^2$ | p    | a   | b   | $r^2$ | p    |
| C$_{max}$ (mM)  | Parent        | 1.04 | 7.45 | 0.807 | <0.001 | 1.12 | 265 | 0.847 | <0.001 |
| t$_{1/2}$ (min) | Parent        | 0.69 | 7.89 | 0.964 | <0.001 | 0.72 | 9.09 | 0.743 | 0.001  |
| Metabolite      |               |     |     |       |        |     |     |       |        |
| AUC$_{0-\infty}$ (mM min) | Parent | 7.88 | 124  | 0.951 | <0.001 | 1.12 | 265 | 0.847 | <0.001 |
| Combined        |               | 8.09 | 32.7 | 0.751 | 0.005  | 0.94 | 76.3 | 0.803 | <0.001 |

PK = a*ePD + b

### Table 5 Linear regression analyses between PK or ePD and iPD

| Treatment  | Compound | PK (ePD) | Unit | iPD   | Unit  | $r^2$ | p    | a    | b    |
|------------|----------|----------|------|-------|-------|-------|------|------|------|
| IV AS      | AS       | V$_2$    | mL kg$^{-1}$ | PCR t$_{1/2}$ | h | 0.724 | 0.002 | 48.5 | −57.2 |
|            |          | C$_{max}$ | mM   | PCR   | min  | 0.596 | 0.009 | 4.83 | 8.45  |
|            |          | Cl       | L kg$^{-1}$ min$^{-1}$ | PCR | Day | 0.534 | 0.02  | 12.5 | −12.2 |
|            | DHA      | AUC$_{0-\infty}$ | mM min | PCR t$_{1/2}$ | h | 0.709 | 0.002 | −32.0 | 767   |
|            |          | AUC$_{0-\infty}$ | mM min | PCR | Day | 0.608 | 0.008 | −48.9 | 780   |
|            |          | t$_{1/2}$ | min | PCR | min | 0.576 | 0.01  | 2.30 | 19.3  |
| AS + DHA   |          | min |     | PCR t$_{1/2}$ | h | 0.772 | 0.0008 | −1.30 | 40.6  |
| DHA        |          | C$_{max}$ | mM | PCR | min | 0.519 | 0.007 | 5.09 | 14.0  |
|            |          | AUC$_{0-\infty}$ | mM min | PCR | Day | 0.596 | 0.009 | −98.5 | 1487  |
| BA         |          | Cl       | L kg$^{-1}$ min$^{-1}$ | PCR t$_{1/2}$ | h | 0.571 | 0.01  | 5.69 | −4.08 |
|            |          | AUC$_{0-\infty}$ | mM min | PCR | min | 0.516 | 0.02  | 87.6 | 71.1  |
| IV AL      | BA       | C$_{max}$ | mM | PCR t$_{1/2}$ | h | 0.615 | 0.04  | 0.447 | 11.0  |
|            |          | C$_{max}$ | mM | PCR | min | 0.611 | 0.04  | 0.665 | 3.82  |

PK = a*ePD + b, or ePD = a*iPD + b
observed in spleen-intact animals. In a tissue distribution study in rats, 1 h following IV administration of AS, high levels of AS were found in brain, fat, intestine and serum, with comparatively low levels in other tissues including liver, kidney, testicle, muscle, fat, heart, eye, spleen and lung [21]. Splenectomy was unlikely to have had a significant effect on the PK parameters and metabolism of AS or AL given the short half-life of both drugs. In light of these findings, the human-rhesus dose conversion factor can be derived based on PK parameters.

Let AUC in human = HA, AUC in Rhesus = RA, dose in human = HD, dose in Rhesus = RD

\[ \frac{\text{AUC per unit dose in human}}{\text{AUC per unit dose in Rhesus}} = \frac{\text{HA}}{\text{HD}} \cdot \frac{\text{RD}}{\text{RA}} \]

\[ F = \frac{\text{HA}}{\text{HD}} \cdot \frac{\text{RD}}{\text{RA}} \]

Since equal AUC for human and Rhesus is desired,

\[ \frac{\text{HA}}{\text{HD}} = \frac{\text{RA}}{\text{RD}} \]

Then,

\[ F = \frac{\text{RD}}{\text{HD}} \]

The ePD of IV AS in uncomplicated P. coatneyi-infected rhesus monkey (8 mg kg\(^{-1}\) dose) can be directly compared to that of patients with uncomplicated falciparum malaria (2 mg kg\(^{-1}\) dose) [22]. Using total drug exposure, AUC values in human vs rhesus (636 vs 476 µM min), the AUC per unit dose for human was 318 and that of rhesus was 59.5. Therefore, the approximate inter-species conversion factor for human in relation to rhesus is 5.34. From Eq. (2), if the human dose = 2 mg kg\(^{-1}\), Rhesus equivalent dose = 5.34*2 = 10.7 mg kg\(^{-1}\)

Vice versa, if the Rhesus dose = 8 mg kg\(^{-1}\),
Human equivalent dose = 8/5.34
= 1.50 mg kg⁻¹.

| Subject | AUC, µmol L⁻¹ | Dose, mg kg⁻¹ |
|---------|---------------|---------------|
| Human   | 636           | Rhesus equi. 10.7 |
| Rhesus  | 476           | 59.5          |
| H/R     | 5.34          | 1.50          |

Values are mean (95 % Confidence interval)

Studies in multiple species [23, 24] have demonstrated limited conversion of AL to DHA. However, we found no DHA in rhesus plasma at all, instead detecting the OHAL metabolite by HPLC-ECD in accordance with a previous report suggesting that this is a product of rhesus monkey microsomes [25]. This finding indicates that the parent drug AL alone contributed to blood stage anti-malarial activity, and is concordant with earlier work also demonstrating in vitro conversion of AL into OHAL in human liver microsomes [25, 26]. Furthermore, the effect of IV AS and IV AL on *P. coatneyi* recrudescence seen here in non-human primates was similar to that seen for *Plasmodium vinckei* in rodents [27], suggesting the possibility that both AS and AL may trigger in vivo parasites dormancy in NHPs. This has been postulated as an underlying mechanism of treatment failure for artemisinin monotherapy [28]. Nevertheless, recrudescence due to short-course artemisinin treatment can be overcome by the use of combination therapy with slow acting anti-malarial agents [29].

Correlation between drug exposure (PK) and drug effect (PD) for artemisinin compounds has been challenging due to rapid clearance of drug, unclear mechanism of action, and sequestration in red blood cells combined with the inability to measure intraerythrocytic drug levels. Parasite clearance, a function of host-parasite-drug interactions, is a good measure of the in vivo drug effect. Davis et al. [30] reported only a borderline significant inverse correlation between AUC and PC50 following IV AS therapy for severe malaria in a 2001 study. Ten years later, White [31] demonstrated that the parasite clearance time was associated with parasite density, potentially confounding PK/PD correlations with artemisinins, and this was borne out in subsequent field studies of oral artemesunate monotherapy [32]. Bakshi et al. [33] developed a PK/PD in vitro system and found that the efficacy of artemisinin depended on Cmax while that of chloroquine depended on its time above minimum inhibitory concentration, TMICh, which were confirmed in an in vivo *Plasmodium berghei*-mouse model. Pooled analysis of data from severe malaria patients following IV AS revealed there was no significant association between PCt1/2 and post hoc population PK estimates. Lastly, children have been found to have lower DHA exposure than adults [34], with a recent study by Hawkes et al. [35] concluding that slower parasite clearance in children relative to adults may be explained by lower DHA exposure. However, they did not observe any correlation between DHA exposure and parasite clearance.

In present study using uncomplicated *P. coatneyi*-Rhesus monkey malaria model, PK-PD analysis of IV AS reveals an inverse linear correlation of DHA’s AUC and Cmax with both PCt1/2 and PCT (Table 5) with longer PCT1/2 and PCT resulting from lower DHA exposure. This is consistent with Hawkes’ conclusion in humans suggesting that the rhesus model mimics human PK/PD for IV AS. Moreover, although AS is rapidly metabolized to DHA following IV administration, parasite clearance appears to be contributed by both components (Fig. 5) and the efficacy of IV AS depends on the t1/2 of combined AS + DHA > Vz of AS > AUC of DHA. In addition, IV AS had strong correlation between PK and iPD (in vivo drug effect against *P. coatneyi*-infected monkey) but not ePD (ex vivo drug effect against *P. falciparum* blood stage) and iPD suggesting that AS and DHA both contributed to in vivo activity against both blood and tissue parasite stages. On the other hand effect kinetic parameter Cmax for IV AL was inversely correlated with PCT1/2. The strong correlation between PK and ePD as well as ePD and iPD implied that the in vivo activity of AL may be predominantly blood stage activity.

**Conclusion**

In a non-human primate model of uncomplicated malaria, IV AS had greater ex vivo potency against *P. falciparum* with higher anti-*P. falciparum* activity during the first 20 min of drug administration. The model demonstrated that parasite clearance was dependent on drug exposure including both AUC and Cmax for both artemisinin regimens. While the efficacy of IV AS depended on the t1/2 of combined AS + DHA, the Vz of AS, and the AUC of DHA, efficacy of IV AL depended largely on its effect kinetic parameter Cmax, and was largely restricted to parent drug activity. As a result, IV AS was selected for further development for the treatment of severe malaria under an Investigational New Drug application (IND) held by the U.S. Army Office of the Surgeon General.
In the United States, it is currently available to patients under an IND treatment protocol maintained at the Centers for Disease Control [36] and by the military.

Additional files

**Additional file 1.** The concentration–time profiles as measured by HPLC-ECD following intravenous artesunate (lysolecithin salt) 11.8 mg/kg in healthy (n = 10) and P. coatneyi infected rhesus monkeys (n = 8). Values are mean and 95% confidence interval of concentration in μmole L⁻¹.

**Additional file 2.** The concentration–time profiles as measured by HPLC-ECD following intravenous artesunate (sodium salt) 8.0 mg/kg in healthy and P. coatneyi infected rhesus monkeys (n = 10 in each group). Values are mean and 95% confidence interval of concentration in μmole L⁻¹.

**Additional file 3.** The antimalarial effect-time profiles as measured by bioassay following intravenous artesunate (lysolecithin salt) 11.8 mg/kg and artemesunate (sodium salt) 8.0 mg/kg in healthy and P. coatneyi infected rhesus monkeys. Values are mean and 95% confidence interval of antimalarial activity expressed as DHA equiv. in μmole L⁻¹.

**Additional file 4.** Parasite-time profiles and recrudescence (R) day following once daily dose of IV AL 11.8, 5.6, 5.6 mg kg⁻¹ and IV AS 8.0, 4.4 mg kg⁻¹ for 3 days, showing mean and 95% confidence interval of percentage (mean and 95% CI) of parasite reduction after treatment.

**Additional file 5.** Pharmacokinetic parameters of parent drug (AL) and metabolite (2-OHAL) and effect kinetic parameters following IV. AL/ Lys 11.8 mg/kg, in healthy and P. coatneyi infected rhesus monkeys with their means, 95% confidence intervals, and coefficient of variation (%CV) values.

**Additional file 6.** Pharmacokinetic parameters of parent drug (AS) and metabolite (DHA) and effect kinetic parameters following IV. AS/Na 8 mg/kg, in healthy and P. coatneyi infected rhesus monkeys with their means, 95% confidence intervals, and coefficient of variation (%CV) values.

**Additional file 7.** Direct comparison of the PK/PD profiles of IV. AL/Lys between healthy self-controls (n = 10) and infected (n = 8) rhesus monkeys. a) Parent drug AL and b) its metabolite 2-OHAL profiles as measured by HPLC-ECD, and c) bioactivity profile as measured by bioassay. Values are mean ± 95% CI.

**Additional file 8.** Direct comparison of the PK/PD profiles of IV. AS/Na between healthy self-controls (n = 10) and infected (n = 10) rhesus monkeys. a) Parent drug AS and b) its metabolite DHA profiles as measured by HPLC-ECD, and c) bioactivity profile as measured by bioassay. Values are mean ± 95% CI.

Authors’ contributions

PIW conceived and participated in the design of the study. RSM participated in the design and execution of the study. MG participated in the design, execution, and analyzed the data of the animal study. PT participated in the execution of the study, conducted the HPLC-ECD analysis and bioassay, performed data analysis, and drafted the manuscript. SK carried out the animal study. DS and NC carried out the HPLC-ECD analysis. MR and AL carried out the bioassay. DLS helped to draft the manuscript. All authors read and approved the final manuscript.

Author details

1 Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, 315/6 Rajvithi Road, Bangkok 10400, Thailand. 2 Department of Veterinary Medicine, Armed Forces Research Institute of Medical Sciences, 315/6 Rajvithi Road, Bangkok 10400, Thailand. 3 Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. 4 Present Address: Director Research Programs, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA. 5 Present Address: US Army Medical Materiel Activity, Ft Detrick, Frederick, MD 21702, USA. 6 Present Address: AAALAC International Southeast Asia Office, Bangpla, Bangplee, Samutprakarn 10540, Thailand. 7 Present Address: Global Health Division, Bill & Melinda Gates Foundation, 250/830 Mool3, Bangpla Soi 18, Seattle, USA.

References

1. World Health Organization. World malaria report. Geneva: World Health Organization; 2015.

2. Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA. 2007;297:2264–77.

3. Chaijaroenkul W, Wisedpanichkij R, Na-Bangchang K. Monitoring of in vitro susceptibilities and molecular markers of resistance of Plasmodium falciparum isolates from Thai–Myanmar border to chloroquine, quinine, mefloquine and artesunate. Acta Trop. 2010;113:190–4.

4. Bartoloni A, Tomasoni L, Bartalesi F, Galli L, Sani S, Velocci S, et al. Combined intravenous treatment with artesunate and quinine for severe malaria in Italy. Am J Trop Med Hyg. 2010;83:274–6.

5. Dondorp A, Nosten F, Stepniewska K, Day N, White N. South East Asian Quinine Artesunate Malaria Trial Group. Artesunate vs quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717–25.

6. Abdallah TM, Elmardi KA, Elhassan AH, Omer MB, Elhag MS, Desogli MA, et al. Comparison of artesunate and quinine in the treatment of severe Plasmodium falciparum malaria at Kassala hospital Sudan. J Infect Dev Ctries. 2014;8:611–5.

7. World Health Organization. Guidelines for the malaria treatment. WHO Guidelines Approved by the Guidelines Review Committee. Geneva: World Health Organization; 2015.

8. Lin AJ, Klayman DL, Milhouw WK. Novel water-soluble antimalarial dihydroartemisinin derivatives. U.S. Patent 4,791,135 1988. Dec 13.

9. Li QG, Si YZ, Lee P, Wong E, Xie LH, Kyle DE, Dow GS. Efficacy comparison of intravenous artelinate and artesunate in Plasmodium berghei-infected Sprague–Dawley rats. Parasitology. 2003;126:283–91.

10. Li Q, Xie LH, Johnson TO, Si Y, Haeberle AS, Weina PJ. Toxicity evaluation of artesunate and artemether in Plasmodium berghei-infected and uninfected rats. Trans R Soc Trop Med Hyg. 2007;101:104–12.

11. Xie LH, Johnson TO, Weina PJ, Si Y, Haeberle A, Lipadthyav R, et al. Risk assessment and therapeutic indices of artesunate and artemether in Plasmodium berghei-infected and uninfected rats. Int J Toxicol. 2005;24:251–64.

12. Smith CD, Brown AE, Nakazawa S, Fujioka H, Aikawa M. Multi-organ erythrocyte sequestration and ligand expression in rhesus monkeys infected with Plasmodium cynomolgi malaria. Am J Trop Med Hyg. 1996;55:379–83.

13. Maeno Y, Brown AE, Smith CD, Tegoshi T, Toyoshima T, Ockenhouse CF, et al. A nonhuman primate model for human cerebral malaria: effects of artesunate (qinghaosu derivative) on rhesus monkeys experimentally infected with Plasmodium coatneyi. Am J Trop Med Hyg. 1993;49:726–34.
14. Teja-Isavadharm P, Peggins JO, Brewer TG, White NJ, Webster HK, Kyle DE. *Plasmodium falciparum*-based assay for measurement of arte‑mesinin derivatives in plasma or serum. Antimicrob Agents Chemother. 2004;48:954–60.

15. Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, Ruangveerayuth R, White NJ. The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur J Clin Pharmacol. 2006;62:1003–9.

16. Li QG, Peggins JO, Lin AJ, Masonic KJ, Trotman KM, Brewer TG. Pharmacology and toxicology of artelinal: preclinical investigations on pharmacokinetics, metabolism, protein and red blood cell binding, and acute and anorectic toxicities. Trans R Soc Trop Med Hyg. 1998;92:332–40.

17. Worldwide antimalarial resistance network. http://www.wwarn.org/toolkit/data-management/parasite-clearance-estimator. Accessed Apr 2015.

18. Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Miller RS, Melendez V, Weina PJ. Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase I study. Am J Trop Med Hyg. 2009;81:615–21.

19. Miller RS, Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Melendez V, et al. Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase I2 study. Malar J. 2012;11:253.

20. Chotivanich K, Udomsangpetch R, McGready R, Proux S, Newton P, Pukrittayakamee S, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis. 2002;185:1538–41.

21. Zhao KC, Song ZY. Distribution and excretion of artesunate in rats. Proc Chin Acad Med Sci Peking Union Med Coll. 1989;4:186–8.

22. Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, White N. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:972–7.

23. Li Q, Xie LH, Si Y, Wong E, Upadhyay R, Yanez D, Weina PJ. Toxicokinetics and hydrolysis of artelinal and artesunate in malaria‑infected rats. Int J Toxicol. 2005;24:241–50.

24. Li QG, Peggins JO, Fleckenstein LL, Masonic K, Heiffer MH, Brewer TG. The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinal acid in rats. J Pharm Pharmacol. 1998;50:173–82.

25. Berman J. MMV annual report: development of an intravenous artemisinin treatment for severe malaria. Discover, develop, deliver, medicines for malaria venture. 2001. p. 29–30.

26. Grace JM, Skanchy DJ, Aguilar AJ. Metabolism of artelinal to dihydroqinqhaosu by human liver cytochrome P4503A. Xenobiotica. 1999;29:703–17.

27. LaCrue AN, Scheel M, Kennedy K, Kumar N, Kyle DE. Effects of artesunate on parasite recrudescence and dormancy in the rodent malaria model *Plasmodium vinckei*. PLoS ONE. 2011;6:e26689.

28. Codd A, Teuscher F, Kyle DE, Cheng Q, Gatton ML. Artemisinin‑induced parasite dormancy: a plausible mechanism for treatment failure. Malar J. 2011;10:56.

29. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965–7.

30. Davis TM, Phuong HL, Illet KF, Hung NC, Batty KT, Phuong VD, et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother. 2001;45:181–6.

31. White NJ. The parasite clearance curve. Malar J. 2011;10:278.

32. Saunders D, Khemawoot P, Vanachayangkul P, Siripokasupkul R, Bethell D, Tyner S, et al. Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated *Plasmodium falciparum* malaria in western Cambodia. Antimicrob Agents Chemother. 2012;56:5484–93.

33. Bakshi RP, Nenortas E, Tripathi AK, Sullivan DJ, Shapiro TA. Model system to define pharmacokinetic requirements for antimalarial drug efficacy. Sci Transl Med. 2013;5:205ra135.

34. Zaloumis SG, Tarning J, Krishna S, Price RN, White NJ, Davis TM, et al. Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. CPT Pharmacometrics Syst Pharmacol. 2014;3:e145.

35. Hawkes MT, Forgie S, Brophy J, Crockett M. Artesunate treatment of falciparum malaria in children. Trans R Soc Trop Med Hyg. 2009;48:546–50.

36. Centers for Disease Control. Guidelines for treatment of malaria in the United States. Atlanta: Centers for Disease Control and Prevention; 2013.